Organic Active Ingredients TRIZ Cases

Combining copanlisib with anti-PD-1 antibodies inhibits PI3K and PD-1 pathways simultaneously.

Selective S1PR2 antagonists address inadequate fibrosis therapies by improving metabolic stability and oral bioavailability.

Oleanolic acid replaces glucocorticoids to control disease symptoms without severe side effects, enabling continuous preventive therapy.

Combining ATR kinase inhibitor Compound A with olaparib targets distinct tumor pathways to produce synergistic cell death effects.

Furo[3,2-c]pyridine compounds inhibit RON and MET kinases to reduce cell proliferation while lowering toxicity from off-target effects.

An N-acetylated chitosan complex protects siRNA from degradation, enabling oral administration to treat inflammatory bowel disease.

A selexipag tablet formulation uses a binder with a specific d(0.9) particle size to enhance dissolution and bioavailability.

A gravimetric filling system creates a contained non-laminar airflow space to enable precise dosing of solid pharmaceutical substances.

Lactose-based water dispersible formulations prevent gelling and improve bioavailability of cefpodoxime proxetil for pediatric patients.

Crystalline tryptamine salts resolve amorphous measurement inaccuracies through controlled phase transitions and X-ray powder diffraction.

Amidoxime carboxylic acid esters resolve solubility bottlenecks in dabigatran prodrugs by enabling simpler formulations and reducing manufacturing costs.

Replacing a sulfamate group with a sulfonamide structure eliminates harmful free ligand release while maintaining enzyme inhibition efficacy.

Selective Pim kinase inhibition blocks EDC3 phosphorylation, reducing systemic side effects while controlling tumor growth.

Imidazopyridine derivatives antagonize Smoothened protein activity, reducing aberrant proliferation and tumor growth in hyperproliferative diseases.

Prepackaged sterile syringes ensure consistent dextrose delivery, resolving manual mixing variability and sterility risks.

Hydroxypropyl methylcellulose and pregelatinized starch stabilize cation-exchange resin suspensions, preventing sediment formation and improving palatability.

Benzothiophene azetidinol suppresses neurodegeneration to extend cognitive function beyond the 48-week limit of symptomatic drugs.

Aceclidine selectively stimulates M1 receptors to enhance near vision while preserving distance clarity and reducing redness.

Hot-melt extrusion of delamanid with vinyl and cellulose polymers prevents thermal degradation while maintaining amorphous stability.

MTA-uncompetitive PRMT5 inhibitors target MTAP-deficient cancer cells.

Amphiphilic micelles encapsulate TLR7 agonists to deliver potent anti-cancer activity without triggering accelerated blood clearance.

Standardized synthesis of ganodermanontriol analogs resolves natural extract variability to ensure consistent bioactivity.

Converting sitosterol into pure TUDCA avoids animal pathogen contamination and isomer separation issues.

An ISRAA polypeptide mediates signals between the nervous and immune systems to treat various disorders.

Modifying the crystal habit of luliconazole through controlled recrystallization enhances solubility and stability, resolving deposition issues during storage.

Flt3L-Fc fusion proteins expand dendritic cells while reducing immunogenicity to improve anti-tumor immune responses.

Lactic acid bacterial exopolysaccharides reduce sleep latency and recovery time through targeted pharmaceutical compositions.

CELMoD compounds degrade WEE1 kinase via Cereblon-mediated ubiquitination, reducing resistance to DNA damaging agents.

Oil-based coating on joint-health ingredients prevents moisture-induced degradation, eliminating complex granulation steps.

Novel 1,3-benzodioxole synthesis method reduces reaction steps from ten to four using acid catalysts and continuous processing.

Cyclopamine analogs resolve insufficient inhibition potency by applying parameter changes to enhance binding affinity against the hedgehog pathway.

Gel-phase liposomal compositions preserve encapsulated agents during freeze-drying, preventing leakage and aggregation that plague liquid-phase formulations.

Combining a drug suspension of micro- or nanoparticles with hyaluronidase reduces tissue resistance to enable sustained release, lowering injection frequency.

Lemborexant stabilizes circadian rhythms via dual orexin antagonism, addressing unmet needs in irregular sleep-wake rhythm disorder management.

Thermal processing of Panax cambial meristematic cells resolves low Rh2 yield by converting abundant common ginsenosides with up to 80% efficiency.

Oral probiotic Enterococcus bacteria enhance humoral and cellular immune responses in felines.

Hydroxy unsaturated fatty acid compounds stimulate or suppress mucosal immunity through targeted structural configurations.

A semisolid aqueous pharmaceutical composition utilizes tapentadol concentration to provide antimicrobial protection without added preservatives.

Substituent patterns on the phenyl ring improve metabolic stability and solubility while reducing cardiac risks.

Triglyceride emulsions with selected fatty acids provide concentrated omega-3 and omega-6 delivery while minimizing undesirable fatty acid interference.

Encapsulated hyaluronic acid fractions manage release profiles via hydrolytically degradable crosslinks, extending retention duration in tissues.

Pamoic acid forms hydrophobic ion pairs with protonatable nitrogen therapeutics in polymeric nanoparticles, resolving burst release and poor drug loading.

Methoxylated biisoquinoline compounds inhibit breast cancer cell growth through selective toxicity mechanisms.

Carboxylic acid-functionalized steroid saponins resolve poor water solubility to enable effective oral administration and systemic bioavailability.